Patents Assigned to Duquesne University of the Holy Spirit
-
Patent number: 11897886Abstract: A compound of Formula II, or optionally a salt or a hydrate of the compound of Formula II is provided: wherein R1 is selected from the group consisting of a hydrogen, an alkyl group having from one to six carbon atoms, an aryl group, and a heteroaryl group; R2 is selected from the group consisting of an alkyl group having from one to six carbon atoms, a hydrogen, a NRaRb group wherein Ra is either a hydrogen or an alkyl group having from one to six carbon atoms and Rb is either a hydrogen or an alkyl group having from one to six carbon atoms, an aryl group, a heteroaryl group, and a halogen; R is an alkyl group having from one to six carbon atoms; and Ar is selected from the group consisting of an alkyl group having from one to six carbon atoms, a substituted aryl, and a substituted heteroaryl.Type: GrantFiled: November 2, 2020Date of Patent: February 13, 2024Assignee: Duquesne University of The Holy SpiritInventor: Aleem Gangjee
-
Publication number: 20240041767Abstract: The present invention is a composition, and a method for making and administering, a pharmaceutical in unit dosage form in which mitochondria-enriched extracellular vesicles are delivered, “as is” or with an optional suitable carrier, after increasing the mitochondria content of the vesicles by generating the vesicles from a human brain endothelial cell line in the presence of one or more suitable promoting agents. Such mitochondria-enriched vesicles are effective to treat tissues needing amelioration of mitochondrial dysfunction or boosting of mitochondrial function. The EVs intrinsically are able to cross the blood-brain barrier and thus are particularly well suited for treating compromised tissues of the brain in situ. as well as other tissues under stress and in need of treatment not limited to neurologic tissues, and are typically administered parenterally.Type: ApplicationFiled: July 27, 2023Publication date: February 8, 2024Applicant: Duquesne University of the Holy SpiritInventor: Devika Soundara Manickam
-
Patent number: 11840539Abstract: The present invention provides substituted pyrrolo-, furano-, and cyclopentylpyrimidine bicyclic pharmaceutical compositions comprising compounds of Formula IV, and pharmaceutically acceptable salts, solvates, and hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, such as for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds and pharmaceutical compositions for treating tumor cells and inhibiting mitosis of cancerous cells.Type: GrantFiled: February 3, 2021Date of Patent: December 12, 2023Assignee: Duquesne University of the Holy SpiritInventor: Aleem Gangjee
-
Patent number: 11629370Abstract: A method of detecting a species, strain or type of bacteria includes mixing a labeled bacteriophage including a label that is detectible via a detection system with a bacterial culture including the species, strain or type of bacteria to which the labeled bacteriophage selectively binds and using the detection system to detect the labeled bacteriophage bound to the species, strain or type of bacteria.Type: GrantFiled: March 16, 2021Date of Patent: April 18, 2023Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, Duquesne University of the Holy SpiritInventors: John Alston Kellum, John D. Hempel, Robert Hugh Edgar, John Andrew Viator
-
Patent number: 11618758Abstract: Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity are provided in the present invention. The compositions of the present invention possess dual activity in a single agent of potent vascular endothelial growth factor receptor inhibitory activity as well as antitubulin activity. Water soluble salts of these compositions are also described. Methods of treating a patient having cancer, macular degeneration, and arthritis with the compositions and salts thereof of the present invention are disclosed.Type: GrantFiled: October 21, 2020Date of Patent: April 4, 2023Assignee: DUQUESNE UNIVERSITY OF THE HOLY SPIRITInventor: Aleem Gangjee
-
Patent number: 11605055Abstract: Novel distractorless authorship verification technology optionally combines with novel algorithms to solve authorship attribution as to an open set of candidates—such as without limitation by analyzing the voting of “mixture of experts” and outputting the result to a user using the following: if z (z=pi?pj? pi+pj?(pi?pj)2/n) is larger than a first predetermined threshold then author j cannot be the correct author; or if z (z=pi?pj? pi+pj?(pi?pj)2/n) is smaller than a second predetermined threshold then author i cannot be the correct author; or if no author garners significantly more votes than all other contenders then none of the named authors is the author of a document in question—in a number of novel applications. Personality profiling and authorship attribution may also be used to verify user identity to a computer.Type: GrantFiled: April 16, 2020Date of Patent: March 14, 2023Assignee: Duquesne University of the Holy SpiritInventors: Patrick Juola, James Orlo Overly, John Isaac Noecker, Michael Ryan, Christine Gray
-
Patent number: 11572363Abstract: This invention provides substituted bicyclic pyrimidine compounds of the following formula: or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of a straight or a branched chain alkyl group having from 1 to 10 carbon atoms, wherein the alkyl group is partially or completely saturated. Methods of treating a patient diagnosed with cancer are disclosed comprising administering to the patient a therapeutically effective amount of the substituted bicyclic pyrimidine compounds, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 22, 2020Date of Patent: February 7, 2023Assignee: Duquesne University of The Holy SpiritInventor: Aleem Gangjee
-
Patent number: 11384084Abstract: A compound of the Formula I and optionally a pharmaceutically acceptable salt thereof is provided: Formula I, wherein, R is one selected from the group consisting of H and CH3; n is an integer 4 when X is —CH2— and Ar is 1,4-phenyl, or n is an integer ranging from 1 to 4 when X is —CH2— and Ar is either 2?-fluoro-1,4-phenyl or 2,5-thienyl, or n is an integer ranging from 1 to 4 when X is one selected from the group consisting of O, S, —NH—, —NHCHO—, —NHCOCH3—, and —NHCOCF3— and Ar is one selected from the group consisting of (a) 1,4-phenyl, (b) 2?-fluoro-1,4-phenyl, and (c) 2,5-thienyl, or n is an integer 3 when X is —CH2—, R is CH3 and Ar is 1,4-phenyl.Type: GrantFiled: August 26, 2020Date of Patent: July 12, 2022Assignees: DUQUESNE UNIVERSITY OF THE HOLY SPIRIT, WAYNE STATE UNIVERSITYInventors: Aleem Gangjee, Larry H. Matherly
-
Patent number: 11124520Abstract: The present invention provides a compound of Formula III, and salts thereof, and a pharmaceutical composition comprising a compound of Formula III: wherein R1 is selected from the group consisting of: wherein R2 is H or an alkyl group having from one to ten carbon atoms; R3 is H or an alkyl group having from one to ten carbon atoms; and R4 is H or an alkyl group having from one to ten carbon atoms. Methods of treating a patient with cancer with these compounds are also provided.Type: GrantFiled: December 4, 2019Date of Patent: September 21, 2021Assignee: Duquesne University of the Holy SpiritInventor: Aleem Gangjee
-
Patent number: 11111252Abstract: The present invention discloses a compound of the formula: and optionally comprising a pharmaceutically acceptable salt or hydrate thereof. A method of treating a patient having cancer or a disease comprising administering to a patient an effective amount of the compound or pharmaceutically acceptable salt or hydrate thereof.Type: GrantFiled: August 11, 2020Date of Patent: September 7, 2021Assignee: Duquesne University of The Holy SpiritInventor: Aleem Gangjee
-
Patent number: 11091500Abstract: The present invention provides tricyclic compounds, and pharmaceutically acceptable salts thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells.Type: GrantFiled: August 2, 2019Date of Patent: August 17, 2021Assignee: Duquesne University of the Holy SpiritInventor: Aleem Gangjee
-
Patent number: 11078214Abstract: The present invention provides a compound of Formula XXVII: wherein X is CH2 or O, and R1 is H or CH3; or a salt or a hydrate of the compound, and further provides a pharmaceutical composition comprising the compound of Formula XXVII and one or more acceptable pharmaceutical carriers. A method of treating a patient having cancer comprising administering a therapeutically effective amount of a compound of Formula XXVII, or a pharmaceutical composition comprising a compound of Formula XXVII and one or more acceptable pharmaceutical carriers to the patient is disclosed.Type: GrantFiled: September 16, 2019Date of Patent: August 3, 2021Assignee: Duquesne University of The Holy SpiritInventor: Aleem Gangjee
-
Patent number: 11053252Abstract: Fused cyclic pyrimidine compounds, including tautomers thereof, and pharmaceutically acceptable salts, prodrugs, solvates and hydrates thereof, are disclosed having the general Formula I: These compounds are useful in methods for treating cancer, selectively targeting cancerous cells via the proton coupled folate transporter, folate receptor alpha, and/or folate receptor beta pathways, inhibiting GARFTase in cancerous cells, and selectively targeting activated macrophages in a patient having an autoimmune disease, such as rheumatoid arthritis.Type: GrantFiled: February 26, 2020Date of Patent: July 6, 2021Assignees: Duquesne University of the Holy Spirit, Wayne State UniversityInventors: Aleem Gangjee, Larry H. Matherly
-
Patent number: 11001595Abstract: The present invention discloses a compound of the formula: wherein R is hydrogen or an alkyl group having from one to ten carbon atoms, or a compound of the formula wherein the S is replaced by CH2 or O, and optionally comprising a pharmaceutically acceptable salt or hydrate thereof. A method of treating a patient having cancer or a disease comprising administering to a patient an effective amount of the compound or pharmaceutically acceptable salt or hydrate thereof.Type: GrantFiled: August 11, 2020Date of Patent: May 11, 2021Assignee: Duquesne University of The Holy SpiritInventor: Aleem Gangjee
-
Patent number: 10961557Abstract: A system for identifying at least one species, strain or type of bacteria in a sample including at least one a labeled bacteriophage which binds selectively to the species, strain or type of bacteria, the at least one labeled bacteriophage comprising a label attached thereto, the system further comprising a detection system adapted to detect the labeled bacteriophage bound to the species of bacteria.Type: GrantFiled: December 19, 2019Date of Patent: March 30, 2021Assignees: University of Pittsburgh Of the Commonwealth System of Higher Education, Duquesne University of the Holy SpiritInventors: John Alston Kellum, John D. Hempel, Robert Hugh Edgar, John Andrew Viator
-
Patent number: 10947246Abstract: The present invention provides substituted pyrrolo-, furano-, and cyclopentylpyrimidine bicyclic compounds of Formula III, and Formula IV, and pharmaceutically acceptable salts, solvates, and hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, such as for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds and pharmaceutical compositions for treating tumor cells and inhibiting mitosis of cancerous cells.Type: GrantFiled: August 7, 2018Date of Patent: March 16, 2021Assignee: Duquesne University of the Holy SpiritInventor: Aleem Gangjee
-
Publication number: 20210035065Abstract: Novel distractorless authorship verification technology optionally combines with novel algorithms to solve authorship attribution as to an open set of candidates—such as without limitation by analyzing the voting of “mixture of experts” and outputting the result to a user using the following: if z (z=pi?pj? pi+pj?(pi?pj)2/n) is larger than a first predetermined threshold then author j cannot be the correct author; or if z (z=pi?pj? pi+pj?(pi?pj)2/n) is smaller than a second predetermined threshold then author i cannot be the correct author; or if no author garners significantly more votes than all other contenders then none of the named authors is the author of a document in question—in a number of novel applications. Personality profiling and authorship attribution may also be used to verify user identity to a computer.Type: ApplicationFiled: April 16, 2020Publication date: February 4, 2021Applicant: Duquesne University of the Holy SpiritInventors: Patrick Juola, James Orlo Overly, John Isaac Noecker, Michael Ryan, Christine Gray
-
Patent number: 10906910Abstract: This invention provides substituted bicyclic pyrimidine compounds of the following formula: or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H and a straight or branched chain alkyl group having from 1 to 10 carbon atoms, wherein the alkyl group is partially or completely saturated, each having tubulin and multiple receptor inhibition properties. Methods of treating a patient diagnosed with cancer are disclosed comprising administering to the patient a therapeutically effective amount of the substituted bicyclic pyrimidine compounds, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 11, 2019Date of Patent: February 2, 2021Assignee: Duquesne University Of The Holy SpiritInventor: Aleem Gangjee
-
Patent number: 10858361Abstract: A compound of Formula II, or optionally a salt or a hydrate of the compound of Formula II is provided: wherein R1 is selected from the group consisting of a hydrogen, an alkyl group having from one to six carbon atoms, an aryl group, and a heteroaryl group; R2 is selected from the group consisting of an alkyl group having from one to six carbon atoms, a hydrogen, a NRaRb group wherein Ra is either a hydrogen or an alkyl group having from one to six carbon atoms and Rb is either a hydrogen or an alkyl group having from one to six carbon atoms, an aryl group, a heteroaryl group, and a halogen; R is an alkyl group having from one to six carbon atoms; and Ar is selected from the group consisting of an alkyl group having from one to six carbon atoms, a substituted aryl, and a substituted heteroaryl.Type: GrantFiled: April 28, 2020Date of Patent: December 8, 2020Assignee: Duquesne University of the Holy SpiritInventor: Aleem Gangjee
-
Patent number: 10844075Abstract: Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity are provided in the present invention. The compositions of the present invention possess dual activity in a single agent of potent vascular endothelial growth factor receptor inhibitory activity as well as antitubulin activity. Water soluble salts of these compositions are also described. Methods of treating a patient having cancer, macular degeneration, and arthritis with the compositions and salts thereof of the present invention are disclosed.Type: GrantFiled: July 2, 2019Date of Patent: November 24, 2020Assignee: Duquesne University of the Holy SpiritInventor: Aleem Gangjee